CDK Inhibitors approved by PBAC 20 April 2018
CDK Inhibitors approved by the Pharmaceutical Benefits Advisory Committee (PBAC) but cost is still an issue. See the link below for further information https://www.bcna.org.au/news/2018/04/cdk-i...
Forum Discussion
Hello,
Thanks for the posts, I have asked our policy team to provide further information regarding special access schemes for Palbociclib and Ribociclib. Stay tuned.
Thanks for the posts, I have asked our policy team to provide further information regarding special access schemes for Palbociclib and Ribociclib. Stay tuned.